osa severity was positively associated with daytime sleepiness and lower quality of life in the eds group. we hypothesised that the prevalence of osa is higher in patients with eds than in a matched control population, and that it contributes to excessive daytime sleepiness, impaired quality of life and aortic disease. conditional logistic regression was used to compare the prevalence of osa and osas between the two groups in an adjusted analysis, adjusting for the matching variables. in a post hoc analysis of the patients with eds only, no difference in ahi was found between solely clinically diagnosed eds (n=17) and objectively confirmed eds (n=83) participants (2.7/hour (1.3–8.7) vs 2.9/hour (1.2–7.2); p=0.55).
to our knowledge, this is the first study to determine the prevalence of osa in patients with eds. the fact that greater weight, male sex and older age were statistically significant predictors of osa among patients with eds suggests a similar pathophysiology for the condition in patients with eds as in the general population. based on our results, we advise clinicians in the care of patients with eds to specifically ask for osa-related symptoms—especially when fatigue and daytime sleepiness are present. because osa may contribute substantially to fatigue, daytime sleepiness and impaired quality of life in this population, patients with eds and excessive daytime sleepiness should be evaluated for osa. tg and mk had full access to all the data in the study and had final responsibility for the decision to submit for publication.
all publications and poster presentations written in english found through august 2018 that describe the prevalence of sleep apnea among people with eds or mfs were included. because prevalence of osa varied among studies, our purpose is to evaluate the prevalence of osa among both eds and mfs and examining moderators possibly affecting the prevalence; in addition, examining difference among common subtypes of eds. nine studies were found to assess the prevalence of osa in patients with eds,8,10–17 whereas 13 studies were found for patients with mfs. although the prevalence of osa in both eds and mfs varied among studies, a consistently high prevalence (ranging between 26% and 100%) was found compared to the rates typically reported for community samples.
in the adult-based study, the prevalence of osa in the eds group was 32% compared to 6% in the comparison group. nonetheless, even when excluding studies that appear to have used sleep clinic populations, the prevalence of osa was still very high among those with eds and mfs. given the low prevalence of eds and mfs, multisite studies that pool data across individuals are needed to better identify potential risk factors for osa among individuals with hypermobility disorders. event rate is the percentage of osa in the group, with overall event rate of 0.39 or 39%.
osa is highly prevalent and under-recognised in eds. because osa may contribute substantially to fatigue, daytime sleepiness and impaired quality of life in the prevalence of osa among people with eds was 39.4% (95% confidence interval [ci] 28.8–51.1, p = .08). in contrast, the prevalence rate among in patients with ehlers-danlos syndrome, abnormal breathing during sleep is commonly unrecognized and is responsible for daytime fatigue and poor sleep., .
research suggests that sleep apnea is relatively common among those with eds. a 2017 study of 100 suggests that 32% of those with ehlers-danlos syndrome have obstructive sleep apnea (compared to just 6% of controls). eds patients are known to suffer from significant sleep problems and excessive daytime sleepiness. eds-features such as increased pharyngeal collapsibility have been proposed to cause obstructive sleep apnea (osa), however this has not been investigated. mild asymptomatic forms of ehlers-danlos syndrome seems to be under diagnosed and may have severe systemic complications mainly cardio vascular. cartilaginous eds features such as genetically related cartilage defects, craniofacial abnormalities and increased pharyngeal collapsibility have been proposed to cause learn about the risks for patients living with eds in osa. emerging science suggest pharmacotherapy may be needed to address eds left behind for some, .
When you try to get related information on eds sleep apnea, you may look for related areas. .